Specialty drug benefit design isn't just one decision — it triggers a domino effect impacting employer and health plan costs, patient access, care delivery and patient cost-sharing. In this episode, we unpack PSG’s latest research on how employers and health plans are rethinking specialty strategies amid rising pressure: cost management as a top priority, movement toward rebate alternatives, shifting site of care models, and evolving approaches to affordability and utilization management. Our guests break down where the biggest shifts are happening, what’s still missing, and how smarter benefit design can create better outcomes across the healthcare system.

PSG (Pharmaceutical Strategies Group)

2025 Trends in Specialty Drug Benefits Report

Specialty Drugs

Drug Utilization

PBM (Pharmacy Benefit Manager)

Copay Assistance (Maximizers & Accumulators)

Drug Rebates

Drug “Carve Outs”

Value-Based Agreements

Utilization Management

Step Therapy

Biosimilars

Site-of-Care

Questions or comments?

Email us at comments@prescriptionforbetteraccess.com.

Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

Folgen-ID: 1000709243948

GUID: 61e4ab22-fb2d-4a8a-a2a6-6427ad07d45c

Erscheinungs­datum: 21.5.2025, 11:00:00